Carter Gould
Stock Analyst at Barclays
(2.57)
# 2,012
Out of 4,817 analysts
204
Total ratings
45.76%
Success rate
-0.64%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $561.49 | +23.78% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $22.04 | +8.89% | 15 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $77.85 | +9.18% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $818.02 | +19.19% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $104.33 | +19.81% | 15 | Apr 22, 2025 | |
| BMY Bristol-Myers Squibb Company | Assumes: Neutral | $55 | $48.94 | +12.38% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $170.16 | +23.41% | 15 | Apr 22, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $100.68 | +63.89% | 12 | Dec 23, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $15.09 | +32.54% | 6 | Nov 1, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $116.49 | +54.52% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $300 → $315 | $273.68 | +15.10% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $69.95 | +42.96% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.69 | +337.06% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.71 | +322.54% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.35 | +566.67% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $37.93 | +150.46% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $20.96 | -4.58% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $61.07 | +19.53% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.33 | +207.69% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $0.97 | +1,132.79% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.81 | +84.50% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.33 | +576.49% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $206.20 | +84.29% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $56.81 | +44.34% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $477.52 | -60.63% | 1 | Jul 26, 2018 |
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $561.49
Upside: +23.78%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $22.04
Upside: +8.89%
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $77.85
Upside: +9.18%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $818.02
Upside: +19.19%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $104.33
Upside: +19.81%
Bristol-Myers Squibb Company
Apr 22, 2025
Assumes: Neutral
Price Target: $55
Current: $48.94
Upside: +12.38%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $170.16
Upside: +23.41%
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $100.68
Upside: +63.89%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $15.09
Upside: +32.54%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $116.49
Upside: +54.52%
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $273.68
Upside: +15.10%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $69.95
Upside: +42.96%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.69
Upside: +337.06%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.71
Upside: +322.54%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.35
Upside: +566.67%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $37.93
Upside: +150.46%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $20.96
Upside: -4.58%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $61.07
Upside: +19.53%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.33
Upside: +207.69%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $0.97
Upside: +1,132.79%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.81
Upside: +84.50%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.33
Upside: +576.49%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $206.20
Upside: +84.29%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $56.81
Upside: +44.34%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $477.52
Upside: -60.63%